E Fund Management Co. Ltd. Sells 1,537 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

E Fund Management Co. Ltd. decreased its holdings in Arcus Biosciences, Inc. (NYSE:RCUS) by 10.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,501 shares of the company’s stock after selling 1,537 shares during the period. E Fund Management Co. Ltd.’s holdings in Arcus Biosciences were worth $258,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of RCUS. GAMMA Investing LLC acquired a new position in shares of Arcus Biosciences during the fourth quarter worth $31,000. Public Employees Retirement System of Ohio acquired a new position in shares of Arcus Biosciences during the third quarter worth $36,000. Strs Ohio acquired a new position in shares of Arcus Biosciences during the third quarter worth $43,000. Exchange Traded Concepts LLC increased its position in shares of Arcus Biosciences by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 6,816 shares of the company’s stock worth $130,000 after purchasing an additional 1,729 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Arcus Biosciences by 27.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 11,850 shares of the company’s stock valued at $226,000 after acquiring an additional 2,516 shares during the period. Institutional investors own 92.89% of the company’s stock.

Insider Buying and Selling

In related news, COO Jennifer Jarrett sold 11,551 shares of the business’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $17.55, for a total transaction of $202,720.05. Following the completion of the transaction, the chief operating officer now owns 215,253 shares in the company, valued at $3,777,690.15. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, President Juan C. Jaen sold 3,900 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $20.06, for a total value of $78,234.00. Following the completion of the sale, the president now directly owns 1,211,365 shares of the company’s stock, valued at $24,299,981.90. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Jennifer Jarrett sold 11,551 shares of the business’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $17.55, for a total transaction of $202,720.05. Following the completion of the sale, the chief operating officer now directly owns 215,253 shares of the company’s stock, valued at $3,777,690.15. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,455 shares of company stock worth $1,014,779. Corporate insiders own 12.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Truist Financial reaffirmed a “buy” rating and issued a $50.00 price target on shares of Arcus Biosciences in a report on Monday, March 25th. Mizuho lowered their price target on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, January 30th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Arcus Biosciences in a report on Thursday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Arcus Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $41.25.

Arcus Biosciences Stock Up 5.8 %

Arcus Biosciences stock traded up $0.89 during mid-day trading on Thursday, reaching $16.15. 967,200 shares of the company’s stock were exchanged, compared to its average volume of 773,900. Arcus Biosciences, Inc. has a twelve month low of $12.95 and a twelve month high of $25.47. The company has a market cap of $1.47 billion, a P/E ratio of -3.89 and a beta of 0.91. The company has a fifty day moving average of $17.01 and a 200-day moving average of $16.58.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.92. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $28.77 million. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The company’s quarterly revenue was up 480.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.09) earnings per share. Equities research analysts expect that Arcus Biosciences, Inc. will post -3.59 earnings per share for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.